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Introduction {#cam41129-sec-0001}
============

Esophageal cancers, including esophageal adenocarcinoma and esophageal squamous cell carcinoma, were the fifth highest in cancer incidence in China, accounting for 50% of all new cases with liver cancer and 49% of cancer‐related deaths worldwide according to the 2014 World Cancer Report [1](#cam41129-bib-0001){ref-type="ref"}. At present, the best strategy to improve the prognosis of esophageal cancer is early detection, diagnosis, and treatment. However, accurate diagnosis with an effective treatment strategy is still a challenge. Several miRNAs have been identified to play fundamental roles in the occurrence and development of cancer, and show altered expression in human various cancers [2](#cam41129-bib-0002){ref-type="ref"}, which motivated us to further explore the potential application of miRNAs in esophageal cancer diagnosis and therapy.

miRNA is a single‐stranded noncoding RNA consisting of 20--24 nucleotides, which functions in suppressing target gene expression by binding to complementary sequences in the 3\_\_‐untranslated region of mRNAs, leading to degradation of mRNA and inhibition of their translation [3](#cam41129-bib-0003){ref-type="ref"}. Complex interactions existing among miRNAs, target genes, and phenotypes have emerged as valuable biomarkers of diagnosis and prognosis associated with various phenotypes in diseases. Since the first report of a direct link between miRNAs and human cancer, in which miR‐15 and miR‐16 were found to be absent or downregulated in B‐cell chronic lymphocytic leukemia, many studies have evaluated their biological roles and associations with disease [4](#cam41129-bib-0004){ref-type="ref"}. Owing to innovations in biotechnology, large datasets have emerged, providing a substantial amount of valuable miRNA data. However, miRNA profiling efforts are often inconsistent between studies because of small sample size, different technological platforms, and different methods for processing and analysis. To overcome these problems, a more advanced and powerful strategy is necessary to handle these comprehensive and complex high‐throughput data. These specific miRNA biomarkers could be applied in early diagnosis and therapy of esophageal cancer in the future.

Methods {#cam41129-sec-0002}
=======

Data collection and processing {#cam41129-sec-0003}
------------------------------

We search for articles in PubMed published from 1999 to 2016 (last accessed on 20 January 2016), by means of the combination of the following key terms: ((esophageal and (cancer\* or carcinoma or tumour\* or tumor\*)) and (microRNA\* or miRNA\* or miR‐\*) and profil\*. In total, we obtain 302 relevant articles, and 217 of them could be downloaded with full text and miRNA profiles from English‐language journals. Further screening filters out 48 papers in which the patient samples are cancer tissues and paired adjacent noncancerous tissues, and not serum samples. To maintain the strategic accuracy and standardize these data as much as possible, the fold change in each miRNA expression is regarded as rule for further screening, and then 12 articles are retained finally.

We download and extract the TCGA data including miRNA expression data, gene expression data and patients\' clinical information from the TCGA Data Portal (<https://tcga-data.nci.nih.gov/tcga/>; last release, March 2016) [5](#cam41129-bib-0005){ref-type="ref"}. Gene expression profiles (Reads per kilobase per million, RPKM) and miRNA expression profiles (reads per million, RPM) are log~2~‐transformed and used for subsequent analysis. In total, 13 pairs of samples are applied to evaluate the expression levels of miRNAs by paired‐samples *t*‐test and their target genes by the DESeq2 program [6](#cam41129-bib-0006){ref-type="ref"} between solid tumors and adjacent noncancerous tissues. The clinical record in 185 esophageal cancer samples is for prognosis analysis.

Standardization of miRNA data {#cam41129-sec-0004}
-----------------------------

Frequently, a miRNA exists as various precursors in primary data. Additionally, the mature form of miRNA always plays crucial roles in regulation of target gene expression. To analyze these data with greater precision and high efficiency, a unified standardization strategy is applied such that the precursors or alias of each miRNA are converted to the corresponding mature form according to the miRBase database (<http://www.mirbase.org/>; last release, Release 21 in June 2014) [7](#cam41129-bib-0007){ref-type="ref"}.

RRA analysis {#cam41129-sec-0005}
------------

The novel RRA method [8](#cam41129-bib-0008){ref-type="ref"}, based on the leave‐one‐out cross‐validation and Bonferroni correction, assigns a *P*‐value to each miRNA in the last aggregated list. The *P*‐value for each miRNA indicates how much better it is ranked compared with a null model, expecting random ordering. With the RRA method, we analyze the ranking miRNA lists based on their fold change in expression level from 12 studies to obtain meta‐signature miRNA. Here, the *P*‐value for each miRNA can indicate whether its expression in esophageal cancer tissues is statistically significant or not, compared with paired normal tissue. The RRA approach is openly available in Comprehensive R Archive Network (<http://cran.r-project.org/>).

Prediction, integration, and verification of target genes {#cam41129-sec-0006}
---------------------------------------------------------

Target genes of these five miRNAs in esophageal cancer are predicted with the miRDB database (<http://mirdb.org/miRDB/>) [9](#cam41129-bib-0009){ref-type="ref"}, TargetScan database (<http://www.targetscan.org/>) [10](#cam41129-bib-0010){ref-type="ref"}, microT‐CDS database (<http://www.microrna.gr/microT-CDS>) [11](#cam41129-bib-0011){ref-type="ref"}, and RNA22 database (<http://cm.jefferson.edu/rna22/>) [12](#cam41129-bib-0012){ref-type="ref"}. Additionally, the experimentally validated target genes of these five miRNAs are searched with the DIANA‐TarBase v7.0 database (<http://www.microrna.gr/tarbase>) [13](#cam41129-bib-0013){ref-type="ref"} and the MiRTarBase database (<http://mirtarbase.mbc.nctu.edu.tw/>) [14](#cam41129-bib-0014){ref-type="ref"}. Then, the target gene lists for each miRNA are generated based on the intersection of the four predicted miRNA target gene databases (miRDB, TargetScan, microT‐CDS, and RNA22) and the union of the two experimentally validated miRNA targeted‐gene databases (DIANA‐TarBase v7.0 and MiRTarBase). Finally, the expression levels of these target genes are tested between 13 paired esophageal cancer and adjacent noncancerous tissues from the TCGA data to obtain significantly differently expressed genes. In theory, upregulation of miRNA expression would lead to downregulation of its target genes and vice versa. Thus, the target genes are confirmed with a further filter (downregulated miRNA: *P* ≤ 0.05 and log~2~ \[fold change\] \>0; upregulated miRNA: *P* ≤ 0.05 and log~2~ \[fold change\] \<0).

Enrichment analysis {#cam41129-sec-0007}
-------------------

To elucidate the biological function of these miRNAs, the candidate target genes are subjected to functional enrichment analyses individually with GeneCodis3 software. The GeneCodis3 (<http://genecodis.cnb.csic.es/>), a web‐based application for singular and modular enrichment analysis, integrates information for various types of data (functional, regulatory, and structural) by searching for frequent patterns among annotations and evaluating statistical relevance [15](#cam41129-bib-0015){ref-type="ref"}. This new approach, superior to DAVID, Onto‐Express, ProfCom or FATIGO+ by overcoming the lack of term--term relationships in these analyses, profiles different sides of the same information and offers a more accurate interpretation of the data.

GeneCodis3 is applied to the functional enrichment analyses (KEGG and Panther pathways) of the significant target genes for each miRNA with a hyp‐c ≤0.05. Here, the hyp‐c, the *P*‐value for the hypergeometric test with multiple hypothesis corrections, represents the significance of the association between each enrichment pathway and the input list of genes.

Prognosis for differentially expressed miRNAs {#cam41129-sec-0008}
---------------------------------------------

The association between miRNA expression and survival for esophageal cancer patients is explored by separating the cases from each cohort into a group with a high expression level and another with a low expression level. The data‐driven approach [16](#cam41129-bib-0016){ref-type="ref"}, a novel computational method for the identification of miRNAs with a significant influence on survival and patient grouping, estimates the optimal threshold expression level for each miRNA for grouping of patients by maximizing the separation of the survival curves related to the risks of the disease. The log‐rank test, based on Kaplan--Meier plots, determines the differences among survival curves with respect to the miRNA expression levels. The univariate HR value, based on the Wald\'s test, determines statistical significance along with 95% CIs in the Cox proportional hazards model.

Results {#cam41129-sec-0009}
=======

Confirmation of five significantly differentially expressed miRNAs in esophageal cancer {#cam41129-sec-0010}
---------------------------------------------------------------------------------------

The general strategy of our study is described in detail in Figure [1](#cam41129-fig-0001){ref-type="fig"}A. We obtained 12 relevant articles [17](#cam41129-bib-0017){ref-type="ref"}, [18](#cam41129-bib-0018){ref-type="ref"}, [19](#cam41129-bib-0019){ref-type="ref"}, [20](#cam41129-bib-0020){ref-type="ref"}, [21](#cam41129-bib-0021){ref-type="ref"}, [22](#cam41129-bib-0022){ref-type="ref"}, [23](#cam41129-bib-0023){ref-type="ref"}, [24](#cam41129-bib-0024){ref-type="ref"}, [25](#cam41129-bib-0025){ref-type="ref"}, [26](#cam41129-bib-0026){ref-type="ref"}, [27](#cam41129-bib-0027){ref-type="ref"}, [28](#cam41129-bib-0028){ref-type="ref"} from the 302 articles with the screening criteria (Fig. [1](#cam41129-fig-0001){ref-type="fig"}B; Table [1](#cam41129-tbl-0001){ref-type="table-wrap"}). The miRNAs data from these 12 articles were then extracted and analyzed with the novel robust rank aggregation (RRA) method [29](#cam41129-bib-0029){ref-type="ref"} to identify miRNAs with statistically significant differences in expression. Overall, 217 miRNAs were upregulated by \>2‐fold and 97 miRNAs were downregulated by \<0.5‐fold. Among them, 14 miRNAs showed integrated significance with the RRA method, including four upregulated miRNAs and 10 downregulated miRNAs (Table [2](#cam41129-tbl-0002){ref-type="table-wrap"}). To validate these 14 miRNAs, their expression levels in 13 paired esophageal cancer and adjacent noncancerous tissue samples from TCGA were reanalyzed. Ultimately, five of them showed significantly different expression, including three upregulated miRNAs (hsa‐miR‐155‐5p, hsa‐miR‐21‐5p, and hsa‐miR‐223‐3p) and two downregulated miRNAs (hsa‐miR‐100‐5p and hsa‐miR‐133b), with *P* ≤ 0.05 (Table [2](#cam41129-tbl-0002){ref-type="table-wrap"}). Notably, previously published quantitative real‐time PCR analyses (RT‐PCR) further supported our results. Hsa‐mir‐155 was upregulated in esophageal squamous cell carcinoma tissues compared to paired adjacent noncancerous tissues [30](#cam41129-bib-0030){ref-type="ref"}. At least two independent studies found that hsa‐mir‐21 was significantly upregulated in tumors compared to normal tissues [31](#cam41129-bib-0031){ref-type="ref"}, [32](#cam41129-bib-0032){ref-type="ref"}. Expression of hsa‐mir‐223 was also markedly increased [33](#cam41129-bib-0033){ref-type="ref"}, [34](#cam41129-bib-0034){ref-type="ref"}. Hsa‐mir‐100 [35](#cam41129-bib-0035){ref-type="ref"} and hsa‐mir‐133b [36](#cam41129-bib-0036){ref-type="ref"}, [37](#cam41129-bib-0037){ref-type="ref"} were notably downregulated in tumor tissues compared to normal tissues. Collectively, these results conclusively demonstrate that compared with adjacent noncancerous tissues, these five miRNAs show significantly different expression in esophageal cancer tissues.

![Flowchart for the study. (A) General strategy of the study. The RRA method (novel robust rank aggregation) was applied to obtaining significant miRNAs. Six databases including TargetScan, miRDB, microT‐CDS,RNA22, miRTarBase, and TarBase v7.0 were applied to obtaining the target genes of the miRNA. The dashed area in A represents the target genes we need. TCGA: The Cancer Genome Atlas. (B) Screening rules for articles on the miRNA expression profile in PubMed.](CAM4-6-1893-g001){#cam41129-fig-0001}

###### 

Characteristics of the analyzed articles

  Reference          Country     Cancer type   No. of tissue samples (cancer/normal)   Technique    No. of miRNAs in show
  ------------------ ----------- ------------- --------------------------------------- ------------ -----------------------
  Feber (2008)       USA         EAC           20 (10/10)                              Microarray   14
  Wijnhoven (2009)   Australia   EAC           14 (7/7)                                Microarray   44
  Fu (2013)          China       ESCC          68 (34/34)                              Microarray   12
  Kong (2011)        China       ESCC          10 (5/5)                                Microarray   22
  Hong (2010)        China       ESCC          20 (10/10)                              Microarray   12
  Kano (2010)        Japan       ESCC          20 (10/10)                              Microarray   15
  Yang (2013)        China       ESCC          6 (3/3)                                 Microarray   15
  Fu (2013)          China       ESCC          18 (9/9)                                Microarray   18
  Saad (2013)        USA         EAC           68 (34/34)                              Microarray   21
  Liu (2013)         China       EAC           6 (3/3)                                 Microarray   60
  Zang (2013)        China       ESCC          6 (3/3)                                 Microarray   65
  Wu (2013)          USA         EAC           70 (35/35)                              Microarray   138

EAC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma.
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###### 

miRNA expression of esophageal cancer samples in published articles and the TCGA

  miRNA                Stem‐loop       miRNA expression in article   miRNA expression in TCGA              
  -------------------- --------------- ----------------------------- -------------------------- ---------- ---------
  **hsa‐miR‐100‐5p**   hsa‐mir‐100     Downregulated                 0.00002                    −1.695     0.04018
  **hsa‐miR‐133b**     hsa‐mir‐133b    Downregulated                 0.02949                    −2.097     0.00451
  **hsa‐miR‐155‐5p**   hsa‐mir‐155     Upregulated                   0.00580                    0.906      0.00136
  **hsa‐miR‐21‐5p**    hsa‐mir‐21      Upregulated                   0.00020                    1.138      0.00008
  **hsa‐miR‐223‐3p**   hsa‐mir‐223     Upregulated                   0.00516                    0.949      0.00197
  hsa‐miR‐424‐5p       hsa‐mir‐424     Upregulated                   0.02595                    −0.10022   0.09163
  hsa‐miR‐375          hsa‐mir‐375     Downregulated                 0.00027                    −1.82663   0.13509
  hsa‐miR‐205‐5p       hsa‐mir‐205     Downregulated                 0.00131                    1.47158    0.41074
  hsa‐miR‐143‐3p       hsa‐mir‐143     Downregulated                 0.00280                    −1.72661   0.10537
  hsa‐miR‐203a‐3p      hsa‐mir‐203a    Downregulated                 0.00699                    −1.09907   0.60401
  hsa‐miR‐192‐5p       hsa‐mir‐192     Downregulated                 0.01563                    0.27979    0.20536
  hsa‐miR‐27b‐3p       hsa‐mir‐27b     Downregulated                 0.02094                    −0.79117   0.15092
  hsa‐miR‐194‐5p       hsa‐mir‐194‐1   Downregulated                 0.03672                    0.07901    0.29485
  hsa‐let‐7c           hsa‐let‐7c      Downregulated                 0.04733                    −1.24124   0.13345

miRNA expression in this article is tested with the novel RRA method. miRNA expression in TCGA is tested with paired *t*‐test (two‐sided). The miRNA with bold text is coincident and significant between published article data and TCGA data.

John Wiley & Sons, Ltd

Predicting, integrating, and verifying target genes {#cam41129-sec-0011}
---------------------------------------------------

To further explore the function and mechanism of these five miRNAs in esophageal cancer, we identified the predicted target genes for each miRNA in six databases with the given integration strategy. The expression levels of these target genes were analyzed in 13 paired esophageal cancer and adjacent noncancerous tissue samples. In total, 1969 target genes were predicted and 686 of these target genes are verified as having significantly different expression between cancer and non‐cancer tissues (*P* ≤ 0.05). Then, 384 target genes were confirmed with a further filter (hsa‐miR‐100‐5p and hsa‐miR‐133b: log~2~ \[fold change\] \>0; hsa‐miR‐155‐5p, hsa‐miR‐21‐5p, and hsa‐miR‐223‐3p: log~2~ \[fold change\] \<0) (Table [3](#cam41129-tbl-0003){ref-type="table-wrap"}).

###### 

Significant miRNA target genes in TCGA

  miRNA        Significant target genes (*P* ≤ 0.05 and the log~2~ \[fold change\])
  ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  miR‐100‐5p   *CDK6, EIF5A, PSMA5, BAZ1B, LSM5, ATP1B3, RNFT1, CLCN5, COL4A1, RAB15, NKX3‐1, RB1, DDX21, EWSR1, YWHAE, NMT1, TTC30A, LIN28B, AP1AR, ABCB6, GNA13, GRB2, WDR4, ORC5, CCZ1B, CTDSPL2*
  miR‐133b     *SMARCD1, MET, ZNF131, FOXC1, COL5A3, SLC39A1*
  miR‐155‐5p   *CAB39L, METTL7A, INA, C3orf18, TTC37, PGRMC2, MITF, CD36, ATPAF1, PCDH9, MUT, TBC1D14, GABARAPL1, PDCD4, KIAA0430, KRCC1, ANAPC16, SETMAR, CDH2, EEF1A2, ZNF652, ERGIC1, RAB11FIP2, SAP30L, ZIC3, PHF17, GPT2, AGTR1, SKIV2L2, GHITM, DMD, ATP6V1H, PNPLA4, STIM1, NOVA1, TAB 2, JUN, SACM1L, CBR4, PCYOX1, ZNF493, GPM6B, OXCT1, AKR1C3, PALLD, CFL2, CAT, HSD17B12, IPO8, LTN1, PAK7, RIOK2, EIF3L, MPP2, UAP1, CYP2U1, FLNA, KANK2, TMBIM6, PIK3R1, MRS2, FOXO3, FGF2, SLC9A3R2, MPP5, MARCH2, PACSIN2, PRKAR2A, ARL6IP5, OSBPL9, ALDH1A2, PEBP1, ALDH3A2, NSA2, SNAP29, AGL, DDX17, ECI1, FAR1, AP1G1, INTS6, CRAT, MAN1A2, GLIPR2, PSIP1, XPC, MLH1, NR3C1, WRB, TNKS1BP1, RBPJ, TMED7‐TICAM2, CLIC4, SMAD4, SOX1, CSNK1A1, C16orf62, UGDH, SPECC1, NCKAP1, LONP2, TSHZ3, ZNF561, TRAK1, CTNNA1, RAB27B, ADH5, RAB6C, CLGN, CHD9, MEF2A, SNTB2, PKIA, LARS*
  miR‐21‐5p    *FOXN3, FBXL17, LONRF2, CPEB3, LIFR, EPM2A, PAIP2B, PGRMC2, TGFBR3, LYRM7, LIMCH1, PDCD4, SASH1, ECI2, GPD1L, FBXL5, ARHGAP24, PURA, NFIA, FMOD, DCAF8, BTG2, CCNG1, ACAT1, KLF9, RNF11, UTRN, NBEA, ZBTB47, RAB11FIP2, DOCK3, SLAIN2, PRKAB2, FBXO3, ELAVL4, C20orf194, ISCU, PPM1L, PHF17, NEK1, RECK, COBLL1, MOAP1, GNAQ, DMD, ZBTB20, PDGFD, DDR2, FKBP5, PBX1, BDH2, FNBP1, MYO9A, TACC1, TIMP3, USP47, CYBRD1, MEGF9, BOC, SACM1L, DYNC1LI2, ATRX, FILIP1L, GOLGA4, ZBTB8A, TPRG1L, PALLD, TCF21, MYEF2, ZNF667, SOD3, PPAP2A, RHOB, WNK3, MKNK2, RUFY3, CALD1, TMX4, PRICKLE2, WFS1, SERPINI1, TUBGCP5, PHACTR2, SLMAP, PIK3R1, ARID4A, FERMT2, FAM63B, RNF38, IPP, SATB1, PER3, WDR47, TGFBR2, WDR7, PIGN, KLHL3, TSC1, MPP5, MON2, SEC63, CDS2, ARHGEF12, REV3L, SYBU, APPL1, AGGF1, JMY, BTBD3, WNK1, SESN1, DAAM1, TMEM56, PRKCE, SERAC1, ZYG11B, APOLD1, SPG11, FIGN, ANKRD46, PTGFR, PKD2, TM9SF3, MPDZ, RXRA, PTEN, CEP104, ITSN2, EIF4EBP2, CLOCK, ATP2B4, DCAF10, HECTD1, EIF2AK3, ZADH2, CSNK1A1, ESYT2, OSR1, CAPN2, DOCK8, NR2C2, MYCBP2, TEK, PTX3, VCL, ZRANB1, CYP4V2, FAM46A, TSHZ3, GPR64, SREK1, NIN, TPM1, PPP1R3B, EIF4A2, ARIH2, RAB6C, MLXIP, MTMR12, ABCD3, PPARA, MEF2A, NEK7, TOPORS, LARS*
  miR‐223‐3p   *SLC2A4, ERO1LB, NFIA, FBXO8, RHOB, NFIX, ZFHX3, FBXW7, EPB41L3*

The targeted genes participating in pathways (KEGG and Panther enrichment pathways) are tested in the TCGA database, and then screening with the rules for hsa‐miR‐100‐5p and hsa‐miR‐133b: *P* ≤ 0.05, and log~2~ (fold change) \>0; hsa‐miR‐155‐5p, hsa‐miR‐21‐5p and hsa‐miR‐223‐3p: *P* ≤ 0.05, and log~2~ (fold change) \<0.
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Functional enrichment of target genes for miRNA {#cam41129-sec-0012}
-----------------------------------------------

Overall, 38 KEGG pathways (Kyoto Encyclopedia of Genes and Genomes), and 22 Panther pathways were enriched for the target genes of hsa‐miR‐100‐5p, hsa‐miR‐133b, hsa‐miR‐155‐5p, hsa‐miR‐21‐5p, and hsa‐miR‐223‐3p.

In the KEGG pathways (Table [4](#cam41129-tbl-0004){ref-type="table-wrap"}), the target genes for hsa‐miR‐100‐5p were involved in cell growth and death, the immune system, the digestive system, and various cancers. Hsa‐miR‐133b functions as a signaling molecule and in cell‐cell interaction, cell communication, the digestive system, and cancer. Hsa‐miR‐155‐5p functions in cell communication, cell motility, transport and catabolism, signal transduction, cancer, and the immune system. Hsa‐miR‐223 functions in cancer protein folding, sorting, and degradation.

###### 

KEGG pathway of the target genes for these five miRNAs

  miRNA                                                Classification                                KEGG pathway                                  Hyp‐c                                            Gene in pathway
  ---------------------------------------------------- --------------------------------------------- --------------------------------------------- ------------------------------------------------ ----------------------------------------------
  miR‐155‐5p                                           Cell communication                            Focal adhesion                                0.036                                            *FLNA, PIK3R1, JUN, PAK7*
  Cell motility                                        Regulation of actin cytoskeleton              0.016                                         *FGF2, CFL2, NCKAP1, PIK3R1, PAK7*               
  Transport and catabolism                             Peroxisome                                    0.023                                         *CAT, CRAT, FAR1*                                
  Signal transduction                                  ErbB signaling pathway                        0.030                                         *PIK3R1, JUN, PAK7*                              
  Cancers                                              Pathways in cancer                            0.004                                         *FGF2, CTNNA1, PIK3R1, JUN, MITF, SMAD4, MLH1*   
  Immune system                                        T‐cell receptor signaling pathway             0.036                                         *PIK3R1, JUN, PAK7*                              
  Toll‐like receptor signaling pathway                 0.037                                         *PIK3R1, JUN, TAB 2*                                                                           
  miR‐21‐5p                                            Cell communication                            Focal adhesion                                0.011                                            *CAPN2, PDGFD, PIK3R1, PTEN, VCL*
  Tight junction                                       0.010                                         *MPP5, PTEN, MPDZ, PRKCE*                                                                      
  Cell growth and death                                p53 pathway feedback loops 2                  0.005                                         *PIK3R1, PTEN, CCNG1*                            
  p53 signaling pathway                                0.009                                         *SESN1, PTEN, CCNG1*                                                                           
  Signal transduction                                  Phosphatidylinositol signaling system         0.012                                         *PIK3R1, CDS2, PTEN*                             
  Wnt signaling pathway                                0.041                                         *PRICKLE2, CSNK1A1, DAAM1*                                                                     
  Folding, sorting, and degradation                    Protein processing in endoplasmic reticulum   0.012                                         *CAPN2, EIF2AK3, SEC63, WFS1*                    
  Cell growth                                          Angiogenesis                                  0.006                                         *TEK, PDGFD, RHOB, PIK3R1, PRKCE*                
  Cancers                                              Pathways in cancer                            0.025                                         *RXRA, APPL1, TGFBR2, PIK3R1, PTEN*              
  Endocrine system                                     Adipocytokine signaling pathway               0.009                                         *RXRA, PRKAB2, PPARA*                            
  Insulin signaling pathway                            0.007                                         *TSC1, MKNK2, PRKAB2, PPP1R3B, PIK3R1*                                                         
  Insulin pathway‐protein kinase B signaling cascade   0.005                                         *TSC1, PIK3R1, PTEN*                                                                           
  Immune system                                        Fc gamma R‐mediated phagocytosis              0.014                                         *PPAP2A, PIK3R1, PRKCE*                          
  miR‐223‐3p                                           Folding, sorting, and degradation             Protein processing in endoplasmic reticulum   0.041                                            *ERO1LB*
  Ubiquitin‐mediated proteolysis                       0.042                                         *FBXW7*                                                                                        
  miR‐100‐5p                                           Cell growth and death                         Cell cycle                                    0.000                                            *CDK6, ANAPC1, YWHAE, ORC2, ORC5, PLK1, RB1*
  Oocyte meiosis                                       0.017                                         *ANAPC1, YWHAE, PLK1*                                                                          
  Replication and repair                               Base excision repair                          0.018                                         *APEX1, HMGB1*                                   
  Cancer                                               Pathways in cancer                            0.011                                         *CDK6, NKX3‐1, GRB2, COL4A1, RB1*                
  Digestive system                                     Protein digestion and absorption              0.012                                         *ACE2, COL4A1, ATP1B3*                           
  Immune system                                        Chemokine signaling pathway                   0.012                                         *CCL7, GRB2, CXCL16, CXCL13*                     
  miR‐133b                                             Cell communication                            Adherens junction                             0.025                                            *MET*
  Focal adhesion                                       0.007                                         *MET, COL5A3*                                                                                  
  Signaling molecules and interaction                  Cytokine‐cytokine receptor interaction        0.048                                         *MET*                                            
  ECM‐receptor interaction                             0.023                                         *COL5A3*                                                                                       
  Cancers                                              Melanoma                                      0.029                                         *MET*                                            
  Renal cell carcinoma                                 0.029                                         *MET*                                                                                          
  Digestive system                                     Protein digestion and absorption              0.024                                         *COL5A3*                                         
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In the Panther pathway analysis (Table [5](#cam41129-tbl-0005){ref-type="table-wrap"}), the target genes for hsa‐miR‐133b were enriched in signal transduction. Hsa‐miR‐155‐5p mainly functions in cancer development and signal transduction. Hsa‐miR‐21‐5p mainly functions in cell growth and death, cancer development, the endocrine system, and signal transduction. Hsa‐miR‐223‐3p functions in cell growth and death, cancer development, and signal transduction. However, no Panther pathway was enriched for target genes of hsa‐miR‐100‐5p.

###### 

Panther pathway of the target genes for hsa‐miR‐100‐5p, hsa‐miR‐133b, hsa‐miR‐155‐5p, hsa‐miR‐21‐5p, and hsa‐miR‐223‐3p

  miRNA                                   Classification                                           Panther pathway                         Hyp‐c                               Target genes in pathway
  --------------------------------------- -------------------------------------------------------- --------------------------------------- ----------------------------------- ---------------------------
  miR‐133b                                Signal transduction                                      Wnt signaling pathway                   0.048                               *SMARCD1*
  miR‐155‐5p                              Development                                              Angiogenesis                            0.048                               *PIK3R1, FGF2, RBPJ, JUN*
  Signal transduction                     Hedgehog signaling pathway                               0.033                                   *PRKAR2A, CSNK1A1*                  
  Wnt signaling pathway                   0.035                                                    *SMAD4, CDH2, CSNK1A1, PCDH9, CTNNA1*                                       
  miR‐21‐5p                               Cell growth and death                                    p53 pathway                             0.028                               *CCNG1, PIK3R1, PTEN*
  p53 pathway by glucose deprivation      0.023                                                    *TSC1, PRKAB2*                                                              
  p53 pathway feedback loops 2            0.015                                                    *CCNG1, PIK3R1, PTEN*                                                       
  PDGF signaling pathway                  0.023                                                    *PIK3R1, MKNK2, RHOB, NIN*                                                  
  Development                             Angiogenesis                                             0.012                                   *PIK3R1, PRKCE, PDGFD, RHOB, TEK*   
  Endothelin signaling pathway            0.025                                                    *PIK3R1, PRKCE, GNAQ*                                                       
  Endocrine system                        Insulin/IGF pathway‐protein kinase B signaling cascade   0.021                                   *PIK3R1, TSC1, PTEN*                
  Signal transduction                     Hypoxia response via HIF activation                      0.027                                   *PIK3R1, PTEN*                      
  PI3 kinase pathway                      0.015                                                    *PIK3R1, GNAQ, PTEN*                                                        
  miR‐223‐3p                              Cell growth and death                                    PDGF signaling pathway                  0.047                               *RHOB*
  Development                             Angiogenesis                                             0.046                                   *RHOB*                              
  Axon guidance mediated by Slit/Robo     0.028                                                    *RHOB*                                                                      
  Cytoskeletal regulation by Rho GTPase   0.032                                                    *RHOB*                                                                      
  Ras Pathway                             0.042                                                    *RHOB*                                                                      
  Signal transduction                     Integrin signaling pathway                               0.041                                   *RHOB*                              
  Notch signaling pathway                 0.033                                                    *FBXW7*                                                                     

No Panther pathway is enriched for target genes of hsa‐miR‐100‐5p.
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Effects of differentially expressed miRNAs on prognosis {#cam41129-sec-0013}
-------------------------------------------------------

To evaluate the prognostic impact of these five candidate miRNAs, survival and Cox regression analyses were applied to determine the risk of death and disease progression related to miRNAs in 185 esophageal cancer patient samples (Table [6](#cam41129-tbl-0006){ref-type="table-wrap"}). Owing to the complexity of miRNA metabolism, we selected the stem‐loop of mature miRNAs to standardize the analysis. The survival analysis results (Fig. [2](#cam41129-fig-0002){ref-type="fig"}) show that hsa‐mir‐100 and hsa‐mir‐133b were significantly associated with 3‐year and 5‐year survival, respectively. However, the other three miRNAs showed no significant difference in both 3‐year and 5‐year survival. Additionally, high hsa‐mir‐223 level was associated with a better prognosis in cancer, in contrast to the other miRNAs.

###### 

Characteristics of the 185 esophageal cancer patients in TCGA

  Characteristics                     Frequency (No.)
  ----------------------------------- -----------------
  Age                                 
  \<40                                1.6% (3)
  40--49                              11.9% (20)
  50--59                              30.3% (56)
  60--69                              18.9% (35)
  70+                                 31.4% (58)
  Unknown                             7.0% (13)
  Sex                                 
  Male                                80.5% (149)
  Female                              12.4% (23)
  Unknown                             7.0% (13)
  Alcohol history                     
  No                                  27.0% (50)
  Yes                                 54.1% (100)
  Unknown                             8.1% (15)
  Smoking history                     
  Nonsmoker                           27.0% (50)
  Current smoker                      19.5% (36)
  ≤15 years                           18.9% (35)
  \>15 years                          18.4% (34)
  Unknown                             16.2% (30)
  Neoplasm histologic grade           
  G1                                  9.7% (18)
  G2                                  38.9% (72)
  G3                                  23.2% (43)
  GX                                  21.1% (39)
  Unknown                             7.0% (13)
  Clinical stage                      
  Stage I                             1.6% (3)
  Stage II                            14.6% (27)
  Stage III                           11.4% (21)
  Stage IV                            5.4% (10)
  Unknown                             67.0% (124)
  Radiation therapy                   
  No treatment                        66.5% (123)
  Treatment                           16.8% (31)
  Unknown                             16.8% (31)
  Treatment prior to surgery          
  No treatment                        26.5% (49)
  Radiation and chemotherapy          1.1% (2)
  Unknown                             74.6% (138)
  Additional pharmaceutical therapy   
  No                                  3.2% (6)
  Yes                                 5.4% (10)
  Unknown                             91.4% (169)

John Wiley & Sons, Ltd

![Prognostic value of miRNA in esophageal cancer. The survival rate analysis and Cox regression analysis are applied to hsa‐miR‐100‐5p, hsa‐miR‐133b, hsa‐miR‐155‐5p, hsa‐miR‐21‐5p, and hsa‐miR‐223‐3p for determination of prognosis in esophageal cancer. Here, the P value for survival analysis describes the significance of the log‐rank. (A) 3‐year‐survival rate analysis and 3‐year‐Cox regression analysis. (B) 5‐year‐survival rate analysis and 5‐year‐Cox regression analysis. HR, hazard ratio; CI, confidence interval.](CAM4-6-1893-g002){#cam41129-fig-0002}

Discussion {#cam41129-sec-0014}
==========

In general, the individual risk grade and decision of treatment largely depend on pathological and clinical factors, which show great variation between individuals, thereby influencing the predictive accuracy in cancer. A recent study demonstrates that differential expression of miRNAs can reflect tissue‐specific expression signatures through promotion or suppression of tumor development and progression [38](#cam41129-bib-0038){ref-type="ref"}. The application of miRNA‐based biomarkers for diagnosis thus provides a promising alternative.

In our study, we identified five differentially expressed miRNAs in esophageal cancer with comprehensive analyses of reported miRNA‐microarray sequencing data, miRNA‐generated sequencing data from the TCGA database, and RT‐PCR data from published studies. Here, we used paired cancer and adjacent noncancerous tissue samples to test miRNA and gene expression, which is more representative of the physiological status in the body than cell or serum samples. These five miRNAs are mainly involving in regulating esophageal cancer occurrence and development, according to comprehensive considerations of KEGG and Panther enrichment analyses. Additionally, high expressions of hsa‐mir‐100 and hsa‐mir‐133b, and low expressions of hsa‐mir‐155 and hsa‐mir‐21 tended to show a better prognosis, especially for hsa‐mir‐100 and hsa‐mir‐133b, which suggested high clinical value for esophageal cancer. Notably, hsa‐mir‐223 levels were increased in cancer tissue compared to normal tissue, but a good prognosis was also associated with a high expression level. In our results, hsa‐miR‐223‐3p mainly participates in protein folding, sorting, and degradation (Tables [4](#cam41129-tbl-0004){ref-type="table-wrap"} and [5](#cam41129-tbl-0005){ref-type="table-wrap"}), which may underlie the anti‐tumor effects. Some studies have regarded the expression levels of different miRNAs as prognostic biomarkers in various cancers such as lung cancer [39](#cam41129-bib-0039){ref-type="ref"}, gastric cancer [40](#cam41129-bib-0040){ref-type="ref"}, and colorectal cancer [41](#cam41129-bib-0041){ref-type="ref"}. In our work, hsa‐miR‐100‐5p, hsa‐miR‐133b, hsa‐miR‐155‐5p, and hsa‐miR‐21‐5p were identified as differentially regulated, and associated with good prognosis; therefore, they can be used as miRNA biomarkers to increase the predictive ability in esophageal cancer, which will provide more choices in the treatment of esophageal cancer with further study. Hsa‐miR‐223‐3p also showed different expression in esophageal cancer tissue. Two or more of these miRNAs as testing indices could further improve the diagnostic accuracy of esophageal cancer.

Some significant target genes in our analysis have been verified experimentally in previous studies, for example, *SMARCD* [42](#cam41129-bib-0042){ref-type="ref"} and *PTEN* [43](#cam41129-bib-0043){ref-type="ref"}, which play important roles in esophageal cancer occurrence and development (Table [5](#cam41129-tbl-0005){ref-type="table-wrap"}). Study of the other genes in Tables [4](#cam41129-tbl-0004){ref-type="table-wrap"} and [5](#cam41129-tbl-0005){ref-type="table-wrap"} may provide more constructive suggestions for esophageal cancer prognosis and treatment.
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